Patents by Inventor Andrew Placzek
Andrew Placzek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240018157Abstract: The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof which are MALT1 inhibitors. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acceptable salts thereof, and methods of using the compounds and compositions for treating diseases, such as cancer, autoimmune disorders, and inflammatory disorders.Type: ApplicationFiled: December 24, 2020Publication date: January 18, 2024Inventors: Shulu Feng, Morgan Lawrenz, Goran Krilov, Andrew Placzek, Zhe Nie, Lynnie Trzoss, Michael Trzoss, Haifeng Tang, H. Rachel Lagiakos
-
Publication number: 20230348424Abstract: The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acceptable salts thereof, and methods of using the compounds and compositions for inhibiting certain protein- protein interactions, and for treating cancer.Type: ApplicationFiled: February 3, 2023Publication date: November 2, 2023Inventors: Adam Marc Levinson, Evelyne Houang, Abba Elias Leffler, Andrew Placzek, Anatoly Ruvinsky, Jeremy Robert Greenwood, Zef Konst, Leah Frye
-
Patent number: 11510887Abstract: Methods of treating a subject having or at risk of developing a neurodegenerative disease or condition associated with demyelination, insufficient myelination, or underdevelopment of myelin sheath are described. The methods include administration of a therapeutically effective amount of sobetirome, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 7, 2020Date of Patent: November 29, 2022Assignees: Oregon Health & Science University, The United States Government as represented by the Department of Veterans AffairsInventors: Thomas S. Scanlan, Meredith Hartley, Andrew Placzek, Marco Righi, Dennis Bourdette, Gail Marracci, Priya Chaudhary
-
Patent number: 11104654Abstract: Ester derivatives of sobetirome with enhanced CNS distribution are disclosed.Type: GrantFiled: July 12, 2019Date of Patent: August 31, 2021Assignee: OREGON HEALTH & SCIENCE UNIVERSITYInventors: Thomas S. Scanlan, Andrew Placzek, Tapasree Banerji, Sky Ferrara, James Matthew Meinig
-
Publication number: 20200405669Abstract: Methods of treating a subject having or at risk of developing a neurodegenerative disease or condition associated with demyelination, insufficient myelination, or underdevelopment of myelin sheath are described. The methods include administration of a therapeutically effective amount of sobetirome, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 7, 2020Publication date: December 31, 2020Applicants: Oregon Health & Science University, The United States Government as represented by the Department of Veterans AffairsInventors: Thomas S. Scanlan, Meredith Hartley, Andrew Placzek, Marco Righi, Dennis Bourdette, Gail Marracci, Priya Chaudhary
-
Patent number: 10870616Abstract: Disclosed are halo substituted derivative compounds of sobetirome with improved pharmacological characteristics relative to sobetirome, pharmaceutical compositions that include those compounds and methods of treating diseases such as neurodegenerative disorders using those pharmaceutical compositions.Type: GrantFiled: December 9, 2019Date of Patent: December 22, 2020Assignee: OREGON HEALTH & SCIENCE UNIVERSITYInventors: Thomas Scanlan, Jordan Devereaux, Andrew Placzek, Tapasree Banerji, Skylar Ferrara, James Matthew Meinig, Tania Banerji
-
Publication number: 20200325092Abstract: Disclosed are halo substituted derivative compounds of sobetirome with improved pharmacological characteristics relative to sobetirome, pharmaceutical compositions that include those compounds and methods of treating diseases such as neurodegenerative disorders using those pharmaceutical compositions.Type: ApplicationFiled: December 9, 2019Publication date: October 15, 2020Applicant: OREGON HEALTH & SCIENCE UNIVERSITYInventors: Thomas SCANLAN, Jordan DEVEREAUX, Andrew PLACZEK, Tapasree BANERJI, Skylar FERRARA, James Matthew MEINIG, Tania BANERJI
-
Publication number: 20200181103Abstract: Ester derivatives of sobetirome with enhanced CNS distribution are disclosed.Type: ApplicationFiled: July 12, 2019Publication date: June 11, 2020Applicant: OREGON HEALTH & SCIENCE UNIVERSITYInventors: Thomas S. Scanlan, Andrew Placzek, Tapasree Banerji, Sky Ferrara, James Matthew Meinig
-
Patent number: 10544075Abstract: Disclosed are halo substituted derivative compounds of sobetirome with improved pharmacological characteristics relative to sobetirome, pharmaceutical compositions that include those compounds and methods of treating diseases such as neurodegenerative disorders using those pharmaceutical compositions.Type: GrantFiled: May 18, 2017Date of Patent: January 28, 2020Assignee: OREGON HEALTH & SCIENCE UNIVERSITYInventors: Thomas Scanlan, Jordan Devereaux, Andrew Placzek, Tapasree Banerji, Skylar Ferrara, James Matthew Meinig, Tania Banerji
-
Patent number: 10392356Abstract: Ester derivatives of sobetirome with enhanced CNS distribution are disclosed.Type: GrantFiled: June 6, 2017Date of Patent: August 27, 2019Assignee: OREGON HEALTH & SCIENCE UNIVERSITYInventors: Thomas S. Scanlan, Andrew Placzek, Tapasree Banerji, Sky Ferrara, James Matthew Meinig
-
Publication number: 20190210950Abstract: Disclosed are halo substituted derivative compounds of sobetirome with improved pharmacological characteristics relative to sobetirome, pharmaceutical compositions that include those compounds and methods of treating diseases such as neurodegenerative disorders using those pharmaceutical compositions.Type: ApplicationFiled: May 18, 2017Publication date: July 11, 2019Applicant: OREGON HEALTH & SCIENCE UNIVERSITYInventors: Thomas SCANLAN, Jordan DEVERAUX, Andrew PLACZEK, Tapasree BANERJI, Skylar FERRARA, James Matthew MEINIG, Tania BANERJI
-
Publication number: 20190175531Abstract: Methods of treating a subject having or at risk of developing a neurodegenerative disease or condition associated with demyelination, insufficient myelination, or underdevelopment of myelin sheath are described. The methods include administration of a therapeutically effective amount of sobetirome, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: February 13, 2019Publication date: June 13, 2019Applicants: Oregon Health & Science University, The United States Government as respresented by the Department of Veterans AffairsInventors: Thomas S. Scanlan, Meredith Hartley, Andrew Placzek, Marco Righi, Dennis Bourdette, Gail Marracci, Priya Chaudhary
-
Patent number: 10226438Abstract: Methods of treating a subject having or at risk of developing a neurodegenerative disease or condition associated with demyelination, insufficient myelination, or underdevelopment of myelin sheath are described. The methods include administration of a therapeutically effective amount of sobetirome, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: February 5, 2014Date of Patent: March 12, 2019Assignees: Oregon Health & Science University, The United States of America as represented by the Department of Veterans AffairsInventors: Thomas S. Scanlan, Meredith Hartley, Andrew Placzek, Marco Righi, Dennis Bourdette, Gail Marracci, Priya Chaudhary
-
Publication number: 20180057472Abstract: Ester derivatives of sobetirome with enhanced CNS distribution are disclosed.Type: ApplicationFiled: June 6, 2017Publication date: March 1, 2018Applicant: OREGON HEALTH & SCIENCE UNIVERSITYInventors: Thomas S. Scanlan, Andrew Placzek, Tapasree Banerji, Sky Ferrara, James Matthew Meinig
-
Patent number: 9701650Abstract: Ester derivatives of sobetirome with enhanced CNS distribution are disclosed.Type: GrantFiled: February 19, 2016Date of Patent: July 11, 2017Assignee: OREGON HEALTH & SCIENCE UNIVERSITYInventors: Thomas S. Scanlan, Andrew Placzek, Tapasree Banerji, Sky Ferrara, James Matthew Meinig
-
Publication number: 20170146519Abstract: Disclosed are small molecules capable of activating the type I interferon (IFN) response by way of the transcription factor IFN regulatory factor 3 (IRF3) were identified. A high throughput in vitro screen yielded 4-(2-chloro-6-fluorobenzyl)-N-(furan-2-ylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxamide (referred to herein as G10), which was found to trigger IRF3/IFN-associated transcription in human fibroblasts. To define cellular proteins essential to elicitation of the antiviral activity by the compound a reverse genetics approach that utilized genome editing via CRISPR/Cas9 technology was employed. This allowed the identification of IRF3, the IRF3-activating adaptor molecule STING, and the IFN-associated transcription factor STAT1 as required for observed gene induction and antiviral effects.Type: ApplicationFiled: November 21, 2016Publication date: May 25, 2017Applicant: OREGON HEALTH & SCIENCE UNIVERSITYInventors: Victor DeFilippis, Tina Sali, Kara Pryke, Jinu Abraham, Andrew Liu, Iris Archer, Kayla Sheridan, Aaron Nilsen, Rebecca Broeckel, Jessica Smith, Lisi Amsler, Daniel Streblow, Andrew Placzek
-
Publication number: 20160244418Abstract: Ester derivatives of sobetirome with enhanced CNS distribution are disclosed.Type: ApplicationFiled: February 19, 2016Publication date: August 25, 2016Applicant: OREGON HEALTH & SCIENCE UNIVERSITYInventors: Thomas S. Scanlan, Andrew Placzek, Tapasree Banerji, Sky Ferrara, James Matthew Meinig
-
Publication number: 20160081955Abstract: Methods of treating a subject having or at risk of developing a neurodegenerative disease or condition associated with demyelination, insufficient myelination, or underdevelopment of myelin sheath are described. The methods include administration of a therapeutically effective amount of sobetirome, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: February 5, 2014Publication date: March 24, 2016Applicants: Oregon Health & Science University, The United States Government as respresented by the Department of Veterans AffairsInventors: Thomas S. Scanlan, Meredith Hartley, Andrew Placzek, Marco Righi, Dennis Bourdette, Gail Marracci, Priya Chaudhary